Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Aberrant PI3K-AKT pathway activation is prevalent in cancers like melanoma.
• AKT1, 2, and 3 (AKT1-3) are key oncoprotein kinases, but direct AKT inhibition has shown limited efficacy.
• Understanding AKT signaling is crucial for developing effective melanoma treatments.

Purpose of the Study:

• To investigate the effects of inhibiting AKT1-3 in melanoma cells.
• To evaluate a novel dual PI3K and mTOR inhibitor for melanoma therapy.
• To assess the efficacy of this dual inhibitor in both treatment-naive and resistant melanoma models.

Main Methods:

• Genetic silencing of all three AKT paralogs (AKT1-3) in melanoma cells.
• Pharmacological inhibition of AKT, PI3K, and mTOR.
• In vitro cell proliferation assays and in vivo tumor growth inhibition studies.
• Testing against patient-derived melanoma xenografts, including MAPK inhibitor-resistant models.

Main Results:

• Genetic silencing of AKT1-3, but not pharmacological inhibition, induced melanoma cell death via mTOR.
• Exogenous AKT1 expression rescued the cell death phenotype in a kinase-dependent manner.
• The dual PI3K/mTOR inhibitor suppressed melanoma cell proliferation in vitro and inhibited tumor growth in vivo.
• The dual inhibitor was well-tolerated and effective against MAPK inhibitor-resistant melanoma xenografts.

Conclusions:

• Targeting PI3K and mTOR simultaneously with a novel dual inhibitor shows therapeutic promise in melanoma.
• This strategy may be effective as a first-line treatment and in cases of MAPK inhibitor resistance.
• Dual PI3K/mTOR inhibition represents a potential therapeutic avenue for melanoma patients.